HT-0712, also known as IPL-455903,[1] is an experimental cognitive enhancing drug (nootropic) which is currently undergoing clinical trials.

It was originally discovered and tested as part of a preclinical anti-inflammatory program by Inflazyme Pharmaceuticals.

CREBs are transcription factors involved in the formation of long-term memory.

A 2014 study found that HT-0712 significantly boosted memory formation in mice.

Data also indicated that HT-0712 may be effective to treat age-associated memory impairment in humans.